(Reuters) - AbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the ...

(Reuters) -Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar of AbbVie's Humira with a list price 81% cheaper than the blockbuster rheumatoid arthritis drug. The ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira® (adalimumab) priced at 95% below ...

The net prices that health plans paid for medicines — after subtracting rebates, discounts, and fees — fell by 2.8% in last year’s fourth quarter, the largest decline ever measured by SSR Health, a ...

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...

The US FDA has already approved two directly interchangeable biosimilars to ABBV's Humira, namely Boehringer Ingelheim's Cyltezo and PFE's ABRILADA. The impact on ABBV's sales may be great, since its ...

A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Blue Shield of California is bypassing traditional pharmacy ...

Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.’s (NYSE:ABBV) Humira, one of the world’s ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The first Humira biosimilar hit the U.S. market a little ...